BenevolentAI Investor Presentation Deck
BenevolentAl is positioned to productionize drug
development
✓ Complete
2020
Chemistry
12
12
2021
Pre-Clinical
2020-2025 In-House Pipeline Progression
On
track
18
16
2022
Ph.I
23
20
2023
Ph. II
29
2024
21
36
...... Un-risked
23
2025
Industry Standard
✓ Delivered 12 named
programmes by end 2021
including 1 Phase I/II (Atopic
Dermatitis) and 1 Preclinical
(Ulcerative Colitis)
✓ Building a deep in-house
clinical pipeline with commercial
launches targeted by end of the
decade
✔ Supplemented by out-licensed
assets
Platform aims to allow continuous programme generation - building a clinical stage pipeline that delivers at
scale
Source: Company filings and estimates. Paul et al (2010) and BIO (2021) for industry standards Confidential
Benevolent 19View entire presentation